Median PFS was @ months ( @ % CI @-@ ) in the rilotumumab @ mg/kg group , @ months ( @-@ ) in the rilotumumab @ mg/kg group , @ months ( @-@ ) in both rilotumumab groups combined , and @ months ( @-@ ) in the placebo group .